HS Linked to Increased Risk for Crohn Disease

06/06/2018

gut

Patients with hidradenitis suppurativa (HS) are at an increased risk for developing Crohn disease, according to the findings of a recent study.

In the cross-sectional study, the researchers identified 51,340 patients with HS using electronic health records data from the Explorys multiple health system data analytics and research platform and 18,455,600 controls. The incidence of Crohn disease was assessed as the primary outcome.

The prevalence of Crohn disease was 2% among patients with HS compared with 0.6% among those without HS.
______________________________________________________________________________________
RELATED CONTENT
Do Patients With HS Have A Higher Risk For Substance Abuse?
What Factors Contribute to Depression and Chronic Pain in Patients with HS?
______________________________________________________________________________________
Additional univariable and multivariable analyses showed that patients with HS had a 3.29 (95% CI, 3.09-3.50) and a 3.05 (95% CI, 2.87-3.25) higher odds of developing Crohn disease, respectively, compared with those without HS.

Patients who were white (2.3%), aged 45 to 64 years (2.4%), nonobese (2.8%), and tobacco smokers (2.3%) had the highest prevalence of Crohn disease. While Crohn disease was associated with HS across all patient subgroups, the association was strongest for men (odds ratio [OR], 3.61; 95% CI, 3.24-4.03), patients aged 45 to 64 years (OR, 3.49; 95% CI, 3.16-3.85), nonobese patients (OR, 4.09; 95% CI, 3.69-4.54), and nonsmokers (OR, 3.44; 95% CI, 3.10-3.82).

“These data suggest that patients with HS are at risk for Crohn disease,” the researchers concluded. “Gastrointestinal symptoms or signs suggestive of Crohn disease warrant additional evaluation by a gastroenterologist.”

Reference

Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States [published online May 23, 2018]. JAMA Dermatol. doi:10.1001/jamadermatol.2018.0878.